全文获取类型
收费全文 | 1395653篇 |
免费 | 109802篇 |
国内免费 | 10365篇 |
专业分类
耳鼻咽喉 | 19828篇 |
儿科学 | 46373篇 |
妇产科学 | 37173篇 |
基础医学 | 194813篇 |
口腔科学 | 35869篇 |
临床医学 | 125045篇 |
内科学 | 273437篇 |
皮肤病学 | 29421篇 |
神经病学 | 106274篇 |
特种医学 | 55683篇 |
外国民族医学 | 745篇 |
外科学 | 210467篇 |
综合类 | 48878篇 |
一般理论 | 388篇 |
预防医学 | 103973篇 |
眼科学 | 31449篇 |
药学 | 107074篇 |
77篇 | |
中国医学 | 9489篇 |
肿瘤学 | 79364篇 |
出版年
2021年 | 11410篇 |
2019年 | 14315篇 |
2018年 | 16143篇 |
2017年 | 13408篇 |
2016年 | 13734篇 |
2015年 | 17265篇 |
2014年 | 23509篇 |
2013年 | 31706篇 |
2012年 | 44057篇 |
2011年 | 46962篇 |
2010年 | 28528篇 |
2009年 | 26297篇 |
2008年 | 42442篇 |
2007年 | 44978篇 |
2006年 | 45089篇 |
2005年 | 44139篇 |
2004年 | 41230篇 |
2003年 | 39741篇 |
2002年 | 38610篇 |
2001年 | 66383篇 |
2000年 | 68941篇 |
1999年 | 58890篇 |
1998年 | 16264篇 |
1997年 | 14921篇 |
1996年 | 14895篇 |
1995年 | 14821篇 |
1994年 | 13971篇 |
1993年 | 12498篇 |
1992年 | 45432篇 |
1991年 | 44175篇 |
1990年 | 42821篇 |
1989年 | 40660篇 |
1988年 | 37358篇 |
1987年 | 36640篇 |
1986年 | 33949篇 |
1985年 | 32532篇 |
1984年 | 24242篇 |
1983年 | 20313篇 |
1982年 | 11733篇 |
1981年 | 10698篇 |
1979年 | 21350篇 |
1978年 | 14782篇 |
1977年 | 12481篇 |
1976年 | 11636篇 |
1975年 | 12575篇 |
1974年 | 14619篇 |
1973年 | 14076篇 |
1972年 | 12925篇 |
1971年 | 11701篇 |
1970年 | 11030篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
2.
Raymond J. Chan RN PhD Vivienne E. Milch MBBS MHPol Fiona Crawford-Williams PhD Oluwaseyifunmi Andi Agbejule BRadTherapy Ria Joseph MNutrDiet Jolyn Johal BND Narayanee Dick BSc Matthew P. Wallen PhD Julie Ratcliffe PhD Anupriya Agarwal MBBS Larissa Nekhlyudov MD Matthew Tieu PhD Manaf Al-Momani BPharm Scott Turnbull PhD Rahul Sathiaraj MPH Dorothy Keefe MBBS MD Nicolas H. Hart PhD 《CA: a cancer journal for clinicians》2023,73(6):565-589
Patient navigation is a strategy for overcoming barriers to reduce disparities and to improve access and outcomes. The aim of this umbrella review was to identify, critically appraise, synthesize, and present the best available evidence to inform policy and planning regarding patient navigation across the cancer continuum. Systematic reviews examining navigation in cancer care were identified in the Cochrane Central Register of Controlled Trials (CENTRAL), PubMed, Embase, Cumulative Index of Nursing and Allied Health (CINAHL), Epistemonikos, and Prospective Register of Systematic Reviews (PROSPERO) databases and in the gray literature from January 1, 2012, to April 19, 2022. Data were screened, extracted, and appraised independently by two authors. The JBI Critical Appraisal Checklist for Systematic Review and Research Syntheses was used for quality appraisal. Emerging literature up to May 25, 2022, was also explored to capture primary research published beyond the coverage of included systematic reviews. Of the 2062 unique records identified, 61 systematic reviews were included. Fifty-four reviews were quantitative or mixed-methods reviews, reporting on the effectiveness of cancer patient navigation, including 12 reviews reporting costs or cost-effectiveness outcomes. Seven qualitative reviews explored navigation needs, barriers, and experiences. In addition, 53 primary studies published since 2021 were included. Patient navigation is effective in improving participation in cancer screening and reducing the time from screening to diagnosis and from diagnosis to treatment initiation. Emerging evidence suggests that patient navigation improves quality of life and patient satisfaction with care in the survivorship phase and reduces hospital readmission in the active treatment and survivorship care phases. Palliative care data were extremely limited. Economic evaluations from the United States suggest the potential cost-effectiveness of navigation in screening programs. 相似文献
3.
Yan Gao MD Yizhen Liu MD PhD Yafei Wang MD Qingyuan Zhang MD Depei Wu MD Xu Ye MD Jianqiu Wu MD Wei Xu MD Jianfeng Zhou MD Yu Yang MD Hong Cen MD Feng Zhang MD Ying Xiang MD Xiaoqiong Tang MD Kaiyang Ding MD JinYing Lin MD Lei Ma MD Shunqing Wang MD Hao Yu MD Yang Zhao MD Bin Song MD Fangfang Lv MD Huiqiang Huang MD 《Cancer》2023,129(4):551-559
4.
5.
6.
7.
8.
Cynthia S. E. Hendrikse MD Phyllis van der Ploeg MD PhD Nienke M. A. van de Kruis MD Jody H. C. Wilting MD Floor Oosterkamp BSc Pauline M. M. Theelen MSc Christianne A. R. Lok MD PhD Joanne A. de Hullu MD PhD Huberdina P. M. Smedts MD PhD M. Caroline Vos MD PhD Brenda M. Pijlman MD Loes F. S. Kooreman MD Johan Bulten MD PhD Marjolein H. F. M. Lentjes-Beer MD PhD Steven L. Bosch MD PhD Anja van de Stolpe MD PhD Sandrina Lambrechts MD PhD Ruud L. M. Bekkers MD PhD Jurgen M. J. Piek MD PhD 《Cancer》2023,129(9):1361-1371
Background
Advanced low-grade ovarian carcinoma (LGOC) is difficult to treat. In several studies, high estrogen receptor (ER) protein expression was observed in patients with LGOC, which suggests that antihormonal therapy (AHT) is a treatment option. However, only a subgroup of patients respond to AHT, and this response cannot be adequately predicted by currently used immunohistochemistry (IHC). A possible explanation is that IHC only takes the ligand, but not the activity, of the whole signal transduction pathway (STP) into account. Therefore, in this study, the authors assessed whether functional STP activity can be an alternative tool to predict response to AHT in LGOC.Methods
Tumor tissue samples were obtained from patients with primary or recurrent LGOC who subsequently received AHT. Histoscores of ER and progesterone receptor (PR) were determined. In addition, STP activity of the ER STP and of six other STPs known to play a role in ovarian cancer was assessed and compared with the STP activity of healthy postmenopausal fallopian tube epithelium.Results
Patients who had normal ER STP activity had a progression-free survival (PFS) of 16.1 months. This was significantly shorter in patients who had low and very high ER STP activity, with a median PFS of 6.0 and 2.1 months, respectively (p < .001). Unlike ER histoscores, PR histoscores were strongly correlated to the ER STP activity and thus to PFS.Conclusions
Aberrant low and very high functional ER STP activity and low PR histoscores in patients with LGOC indicate decreased response to AHT. ER IHC is not representative of functional ER STP activity and is not related to PFS. 相似文献9.